首页> 外文期刊>Transplantation Proceedings >Noninvasive therapy of incidental de novo renal cell carcinoma in a kidney allograft 12 years after transplantation: report of a case and review of literature.
【24h】

Noninvasive therapy of incidental de novo renal cell carcinoma in a kidney allograft 12 years after transplantation: report of a case and review of literature.

机译:移植后12年的肾脏同种异体移植中从发性新生肾细胞癌的无创治疗:病例报告和文献复习。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Immunosuppressive therapy increases the incidence of posttransplantation cancer. Primary renal cell carcinoma (RCC) represents 4.6% of all cancers in transplant recipients. The treatment options for RCC in a renal allograft include radical nephrectomy or nephron-sparing surgery. We report the case of a patient who underwent percutaneous radiofrequency ablation (RFA) of a RCC in the grafted kidney. PATIENT AND METHODS: Twelve years after undergoing heterotopic, allogenic kidney transplantation, a de novo lesion was diagnosed in the upper pole of the kidney graft in a 77-year-old patient during routine duplex ultrasonography. The magnetic resonance image showed a spherical lesion of 17 mm in diameter, which undoubtedly showed radiological signs of a RCC. After adequately informing the patient about alternative treatment strategies and the associated risks, we made an interdisciplinary decision for a percutaneous RFA of the lesion. RESULTS: After the intervention, graft function remained unchanged and is still good at 6 months with no signs of local recurrence on follow-up MRI. A small coagulation defect at the site of the former lesion was the only morphological change. There was also no evidence of distant tumor spread. CONCLUSION: Percutaneous RFA seems an acceptable, allograft-preserving treatment option associated with low morbidity and mortality for RCC in a renal allograft considering the significant risks associated with open partial nephrectomy in a kidney graft.
机译:背景:免疫抑制疗法增加了移植后癌症的发生率。原发性肾细胞癌(RCC)占移植接受者所有癌症的4.6%。肾同种异体肾癌的治疗选择包括根治性肾切除术或保留肾单位的手术。我们报道了一例在移植肾中进行了RCC的经皮射频消融(RFA)的患者。患者和方法:异位异体肾脏移植十二年后,在常规双路超声检查中,一名77岁患者的肾脏移植物上极被诊断为新生病变。磁共振图像显示出直径为17 mm的球形病变,这无疑显示出RCC的放射学体征。在充分告知患者替代治疗策略和相关风险之后,我们对病变的经皮RFA做出了跨学科决策。结果:干预后,移植物功能保持不变,并在6个月时仍保持良好状态,随访MRI没有局部复发的迹象。前病变部位的一个小的凝血缺陷是唯一的形态学改变。也没有证据表明远处的肿瘤扩散。结论:考虑到与肾部分开放性部分肾切除术相关的重大风险,经皮射频消融似乎是一种可以接受的,保留同种异体移植的治疗选择,与肾同种异体肾癌的低发病率和死亡率相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号